TransMedics Group (TMDX) Price & Analysis

Compare

1,563 Followers

TMDX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$55.00 - $177.37

Previous CloseN/A

Volume1.17M

Average Volume (3M)1.25M

Market Cap

$4.35B

Enterprise Value$5.55B

Total Cash (Recent Filing)$400.57M

Total Debt (Recent Filing)$518.82M

Price to Earnings (P/E)66.0

Beta1.25

Next Earnings

Nov 11, 2025

EPS Estimate

0.36

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.92

Shares Outstanding34,090,355

10 Day Avg. Volume1,161,540

30 Day Avg. Volume1,245,319

Financial Highlights & Ratios

PEG Ratio-0.24

Price to Book (P/B)9.06

Price to Sales (P/S)4.69

P/FCF Ratio-25.60

Enterprise Value/Market Cap1.28

Enterprise Value/Revenue10.45

Enterprise Value/Gross Profit17.48

Enterprise Value/Ebitda49.61

Forecast

1Y Price Target

$146.71

Price Target Upside15.02% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Clinical TrialsFDA conditional approval for the Next-Generation OCS Heart ENHANCE clinical program is a pivotal step in redefining heart transplant care.

Financial PerformanceTransMedics reported strong second-quarter results, with sales increasing roughly 38% to $157.4 million, surpassing expectations.

Revenue GuidanceManagement raised their 2025 revenue guidance, projecting top-line growth of roughly 35% at the midpoint.

Bears Say

LogisticsScheduled maintenance for TMDX's aviation fleet is expected in Q3 and Q4, potentially impacting logistics temporarily.

Market EnthusiasmUS enthusiasm for lung perfusion has been tepid due to 'poor and equivocal' outcomes from non-portable, non-blood-based systems.

TransMedics Group News

TransMedics approved by FDA for Next-Generation OCS Heart Trial

TransMedics (TMDX) Group announced that the U.S. FDA has granted conditional approval of its Investigational Device Exemption, allowing...

14d ago

TMDX

TransMedics price target raised to $152 from $148 at Baird

Baird analyst David Rescott raised the firm’s price target on TransMedics (TMDX) to $152 from $148 and keeps...

18d ago

TMDX

TransMedics reports Q2 EPS 92c vs. 35c last year

Reports Q2 revenue $157.4M, consensus $147.75M. “We are proud to report another strong quarter, marked by profitable year-over-year...

19d ago

TMDX

TransMedics raises FY25 revenue view to $585M-$605M from $565M-$585M

FY25 consensus $582.06M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try...

19d ago

TMDX

TransMedics Group’s OCS Lung: A Game-Changer in Organ Care with Promising Clinical Advancements

TransMedics Group, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from...

6d ago

TMDX

TransMedics Group: Strong Performance and Strategic Initiatives Drive Buy Rating

Analyst William Plovanic from Canaccord Genuity maintained a Buy rating on TransMedics Group and keeping the price target...

6d ago

TMDX

TransMedics Group’s Strategic Advancements and FDA Approval Drive Buy Rating

Josh Jennings, an analyst from TD Cowen, maintained the Buy rating on TransMedics Group. The associated price target...

14d ago

TMDX

TransMedics Group Q2 2025 Earnings Call Highlights

Transmedics Group (($TMDX)) has held its Q2 earnings call. Read on for the main highlights of the call....

18d ago

TMDX

TransMedics Reports Strong Q2 2025 Financial Results

Transmedics Group ( ($TMDX) ) has released its Q2 earnings. Here is a breakdown of the information Transmedics...

19d ago

TMDX

TransMedics Group: Strong Financial Performance and Optimistic Outlook Justify Buy Rating

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on TransMedics Group, with...

19d ago

TMDX

Buy Rating for TransMedics Group Amid Strong Q2 Prospects and Seasonal Challenges

William Blair analyst Ryan Daniels has maintained their bullish stance on TMDX stock, giving a Buy rating on...

21d ago

TMDX

Cautious Optimism for TransMedics Group Amid Strong Growth Indicators

Needham analyst Michael Matson has maintained their neutral stance on TMDX stock, giving a Hold rating on July...

27d ago

TMDX

TransMedics Group: Strong Market Position and Ethical Practices Justify Buy Rating Amid Controversies

TD Cowen analyst Josh Jennings has maintained their bullish stance on TMDX stock, giving a Buy rating on...

28d ago

TMDX

TransMedics price target raised to $142 from $129 at Canaccord

Canaccord analyst William Plovanic raised the firm’s price target on TransMedics (TMDX) to $142 from $129 and keeps...

1M ago

TMDX

TMDX FAQ

What was TransMedics Group Inc’s price range in the past 12 months?

TransMedics Group Inc lowest stock price was $55.00 and its highest was $177.37 in the past 12 months.

What is TransMedics Group Inc’s market cap?

TransMedics Group Inc’s market cap is $4.35B.

When is TransMedics Group Inc’s upcoming earnings report date?

TransMedics Group Inc’s upcoming earnings report date is Nov 11, 2025 which is in 84 days.

How were TransMedics Group Inc’s earnings last quarter?

TransMedics Group Inc released its earnings results on Jul 30, 2025. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.47.

Is TransMedics Group Inc overvalued?

According to Wall Street analysts TransMedics Group Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does TransMedics Group Inc pay dividends?

TransMedics Group Inc does not currently pay dividends.

What is TransMedics Group Inc’s EPS estimate?

TransMedics Group Inc’s EPS estimate is 0.36.

How many shares outstanding does TransMedics Group Inc have?

TransMedics Group Inc has 34,090,355 shares outstanding.

What happened to TransMedics Group Inc’s price movement after its last earnings report?

TransMedics Group Inc reported an EPS of $0.92 in its last earnings report, beating expectations of $0.45. Following the earnings report the stock price went up 10.464%.

Which hedge fund is a major shareholder of TransMedics Group Inc?

Currently, no hedge funds are holding shares in TMDX

TransMedics Group Stock Smart Score

Neutral

Fundamentals

Return on Equity

28.21%

Trailing 12-Months

Asset Growth

17.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

TransMedics Group (TMDX) Earnings & Revenues

Historic Earnings Reports

TMDX Company Deck

TMDX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

TransMedics demonstrated strong financial performance in Q2 2025, with record revenue growth and a healthy cash position. The company is making progress on key clinical programs and has raised its full-year guidance. However, it faces ongoing challenges in the lung perfusion market and anticipates some seasonal impacts in Q3. Overall, the company's strengths and positive developments outweigh the challenges.View all TMDX earnings summaries

TMDX Stock 12 Month Forecast

Average Price Target

$146.71

▲(15.02% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"61":"$61","116":"$116","171":"$171","88.5":"$88.5","143.5":"$143.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$170.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":146.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$146.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":123,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$123.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[61,88.5,116,143.5,171],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,120.55,124.35384615384615,128.15769230769232,131.96153846153845,135.76538461538462,139.56923076923076,143.37307692307692,147.17692307692306,150.98076923076923,154.7846153846154,158.58846153846153,162.3923076923077,166.19615384615383,{"y":170,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,120.55,122.56230769230768,124.57461538461538,126.58692307692307,128.59923076923076,130.61153846153846,132.62384615384616,134.63615384615386,136.64846153846153,138.66076923076923,140.67307692307693,142.68538461538463,144.6976923076923,{"y":146.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,120.55,120.73846153846154,120.92692307692307,121.11538461538461,121.30384615384615,121.49230769230769,121.68076923076923,121.86923076923077,122.0576923076923,122.24615384615385,122.43461538461538,122.62307692307692,122.81153846153846,{"y":123,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":151.51,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":168.06,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":144.82,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.55,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.32,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.27,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.94,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >